brain implant therapy for epilepsy and other discorders

A Breakthrough in Brain Implants for Epilepsy and Beyond

Oran Knowlson's Journey with Lennox-Gastaut Syndrome

The First Trial of a Revolutionary Brain Implant

Oran Knowlson, a British teenager diagnosed with Lennox-Gastaut syndrome, a severe form of epilepsy, made history by becoming the first person to trial a new brain implant last October. The results were nothing short of phenomenal, with an 80% reduction in his daytime seizures. According to Martin Tisdall, a consultant paediatric neurosurgeon at Great Ormond Street Hospital (GOSH) in London, this had a profound impact on Oran's life, significantly reducing falls and injuries caused by seizures.

Improved Quality of Life and Cognition

The brain implant, known as Picostim, not only reduced Oran's seizures but also led to improvements in his cognition. His mother observed that he became more alert and engaged, marking a significant enhancement in his overall quality of life. The implant, which sits under the skull, continuously sends electrical signals deep into the brain, blocking abnormal impulses that trigger seizures.

Understanding the Technology Behind Picostim

The Mechanics of the Neurostimulator

Picostim, approximately the size of a mobile phone battery, is recharged via headphones and operates differently between day and night. This cutting-edge device not only sends electrical impulses but also records brain activity. According to Tisdall, this ability to monitor neural patterns could pave the way for enhancing the efficacy of the stimulation provided to patients like Oran.

The Potential for NHS Integration

With the success of Oran's trial, there are plans to extend the pilot to three more children with Lennox-Gastaut syndrome in the coming weeks, followed by a full trial involving 22 children early next year. If these trials are successful, Great Ormond Street Hospital and University College London, the academic sponsors, will apply for regulatory approval. Tim Denison, a professor of engineering science at Oxford University and co-founder of Amber Therapeutics, the company that developed the implant, hopes to make this device available on the NHS within four to five years.

The Growing Field of Neural Implants

A Wide Range of Applications

The technology behind Picostim is part of a broader trend in neural implants designed to treat various conditions, including brain cancer, chronic pain, rheumatoid arthritis, Parkinson's incontinence, and tinnitus. Unlike earlier implants, these new devices not only decode brain signals but also regulate them, marking a significant advancement in neuromodulation technology.

Competing Innovations: Europe vs. The US

Europe is positioning itself as a leader in the development of this life-changing technology, competing head-to-head with the US. Amber Therapeutics is one of many companies innovating in this space. For example, California-based NeuroPace has developed a device for epilepsy that responds to abnormal brain activity, though it lacks the rechargeable feature of Picostim and requires surgical replacement after a few years.

The Broader Implications of Brain Implants

The Intersection of Technology and Healthcare

The brain implant sector is expanding rapidly, with numerous companies across the globe working on different aspects of brain-computer interfaces (BCIs) and deep brain stimulation. While companies like Elon Musk's Neuralink focus on decoding brain signals for actions, Amber and others are moving towards therapeutic modulation of these signals to treat illnesses.

Ethical Considerations and Future Research

As these technologies advance, ethical considerations around their use, particularly in vulnerable populations like children with severe neurological conditions, are paramount. The future of research will likely focus on optimizing these implants for various patient populations, minimizing side effects, and exploring long-term efficacy.

European Innovations in Brain Implants

The Pioneering Role of Amber Therapeutics

Amber's implant is not only being tested for epilepsy but also for other conditions such as Parkinson's disease, chronic pain, and multiple system atrophy. Early trials, including those for incontinence in Belgium, have shown promising results, highlighting the versatility and potential of this technology.

Graphene-Based Implants: A New Frontier

In a few weeks, the first brain implant made of graphene, developed by Inbrain Neuroelectronics in collaboration with Manchester University, will be tested in human. This ultra-thin, carbon-based material is not harmful to human tissue and offers high precision in decoding and modulating neural activity. The upcoming clinical trial at Salford Royal Hospital will test this implant on a patient with glioblastoma, a fast-growing brain cancer.

The Future of AI-Power Implants

Inbrain is also developing AI-powered implants with 1,024 electrical contracts, designed to deliver personalized therapy without the need for manual programming by neurologists. This technology aims to treat severe chronic inflammatory, metabolic, and endocrine diseases by stimulating the vagus nerve.

The Growing Bioelectronics Market

Global Market Projections

The bioelectronics market, which integrates biological science and electrical engineering, is currently valued at $8.7 billion and is expected to exceed $20 billion by 2031. This field which includes both peripheral nervous system-focused devices and brain neuromodulation technologies, holds significant promise for treating a wide range of conditions.

European Startups Leading the Way

In addition to established companies, European startups are making significant strides in this field. For instance, MintNeuro, a spinout from Imperial College London, is developing next-generation chips that can be integrated into tiny implants.

Conclusion

The Path Forward in Neuromodulation

The advancements in brain implant technology, as demonstrated by Oran Knowlson's case, represent a significant milestone in the treatment of neurological disorders. As research and development continue, these devices could offer new hope to patients worldwide, transforming the way we approach the treatment of epilepsy, chronic pain, and other debilitating conditions. The race between Europe and the US to bring these innovations to market will likely accelerate, leading to widespread adoption and improved patient outcomes globally.

Source